SCHEMBL700768

SCHEMBL700768

CC(=O)c1ccc(-c2ccc(C(=O)O)cc2)o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
HPGD P15428 2/20 0.56
KDM4E B2RXH2 4/20 0.56
TDP1 Q9NUW8 2/20 0.56
NQO2 P16083 5/20 0.51
MAPT P10636 3/20 0.50
TP53 P04637 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
PTPN1 P18031 1/20 0.49
PTPN11 Q06124 1/20 0.49
PSMD14 O00487 1/20 0.48
MMP2 P08253 1/20 0.48
PTPN7 P35236 1/20 0.48
DUSP3 P51452 1/20 0.48
KEAP1 Q14145 1/20 0.47
NFE2L2 Q16236 1/20 0.47
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2557432 0.86 ALDH1A1 (0.66) ALDH1A1HPGDKDM4ENQO2MAPT
SCHEMBL30175787 0.84 ALDH1A1 (0.73) ALDH1A1HPGDKDM4ENQO2MAPT
SCHEMBL8805929 0.83 ALDH1A1 (0.67) ALDH1A1HPGDKDM4ENQO2MAPT
SCHEMBL16346518 0.83 HPGD (0.53) ALDH1A1HPGDKDM4ETDP1NQO2
SCHEMBL702364 0.83 MAPT (0.51) ALDH1A1HPGDKDM4ETDP1NQO2
SCHEMBL5963142 0.82 TDP1 (0.69) ALDH1A1HPGDKDM4ETDP1NQO2
SCHEMBL700838 0.80 POLB (0.60) ALDH1A1HPGDKDM4ETDP1MAPT
SCHEMBL11813532 0.80 ALDH1A1 (0.50) ALDH1A1HPGDKDM4ENQO2MAPT
SCHEMBL13078607 0.80 SLC9A1 (0.59) ALDH1A1HPGDKDM4ENQO2MAPT
SCHEMBL9477782 0.80 ALDH1A1 (0.69) ALDH1A1HPGDMAPTTP53RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
CN-102137866-A Oxindole compounds CYLENE PHARMACEUTICALS INC 2011-07-27 CN disclosed
EP-2307421-A1 OXINDOLE COMPOUNDS Cylene Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041635-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 ALDH1A1 2525/4885HPGD 2227/4885KDM4E 1018/4885
US-20120190669-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 ALDH1A1 2525/4885HPGD 2227/4885KDM4E 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.